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Abstract
Background: Danlou tablets, a patented Chinese Medicine, have been long approved for the treatment of
ischemic heart disease in China. While numerous empirical observations suggested Danlou tablets could decrease
frequency and duration of angina pectoris attacks, evidence supporting its efficacy on cardiac remodeling remains
inadequate. Therefore, this pilot trial was designed to determine whether Danlou tablets would reduce adverse left
ventricular (LV) remodeling in patients with myocardial infarction (MI).
Methods and Results: Eligible patients with acute MI were enrolled and randomly assigned to Danlou tablets or
placebo groups, superimposed on standard treatment for MI. Then, in addition to assessment of the clinical outcome,
the changes in LV volumes were evaluated by a serial echocardiography. In total, 83 patients (Danlou tablets 42 and
placebo 41) completed 90 days of treatment and had complete baseline and outcome data. Standard echocardiographic
evaluations revealed significant differences in the change of LV end-diastolic volume index (LVEDVi) between group of
patients treated with Danlou tablets and the placebo group (−4.49 ± 7.29 vs. −0.34 ± 9.01 mL/m2, P < 0.001). The
reduction in LVEDVi was independent of beta-blocker, ACE inhibitors/ARBs use. Furthermore, treatment with Danlou
tablets significantly reduced LV end-systolic volume index (−4.09 ± 5.85 vs. −0.54 ± 5.72 mL/m2, P < 0.001) and improved
the LV ejection fraction (4.83 ± 9.23 vs. 0.23 ± 8.15 %, P < 0.001), as compared to placebo. Meaningfully, the incidence of
the major adverse cardiovascular events was also lower in patients receiving Danlou tablets (P < 0.05).
Conclusion: Superimposed on the standard pharmacologic treatment, Danlou tablets significantly reversed post-MI
adverse LV remodeling, thereby contributed to the overall positive clinical outcome.
Trial registration: clinicaltrials.gov identifier NCT02675322 (February 1, 2016).
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Background
Adverse left ventricular (LV) remodeling after myocar-
dial infarction (MI) has been shown to be associated
with an increased risk for adverse cardiovascular events,
whereas the progressive deterioration of cardiac per-
formance is an important warning sign of the developing
heart failure and a significant predictor of all-cause
mortality [1–3]. To date, several therapeutic approaches
have been exercised in patients afflicted with acute MI,
including local coronary reperfusion and systemic treat-
ments with inhibitors of angiotensin converting enzyme
(ACE), beta-adrenergic blockers, as well as application of
pharmacologic or electrical cardiac resynchronization
[4–7]. While numerous clinical trials already proven that
these methods prevent development of the LV dilatation
to a certain degree, the incidences of the adverse LV
remodeling, still observed in a substantial proportion of
patients after MI, remains the major challenge for mod-
ern medicine [8, 9]. Therefore, there is a constant need
for development of novel and more efficient therapies
that would reverse LV remodeling and reduce the
incidence of major cardiac events.
Over the past few years, numerous components of the
traditional Chinese Medicine (TCM) that would exert
cardioprotective effects, received a great deal of attention
and have been tested for their abilities in alleviating symp-
toms of angina pectoris, myocardium infarction, heart
failure, arrhythmia, and other cardiovascular conditions
[10–14]. In particular, Danlou tablets (consisting of Salvia
miltiorrhiza, Ligusticum chuanxiong Hort, Trichosanthes
kirilowii, Allium macrostemon Bung, Radix Paeoniae
Rubra, Radix Puerariae, rhizoma alismatis, Curcuma
aromatic, Rhizoma Drynariae, and Astragalus membrana-
ceus) known for their anti-oxidant and anti-inflammatory
action, have been successfully used by TCM practitioners,
for stabilizing atherosclerotic plaques and reduction of the
ischemia reperfusion injury [15–17]. From the perspective
of TCM, the negative outcome of MI is mostly caused by
accumulation of intracardiac “phlegm” and obstruction of
coronary circulation. It has been also suggested that treat-
ments of patients with Danlou tablets may contribute to
elimination of “phlegm” and restoration of inadequate
blood circulation in the afflicted hearts [18, 19]. Therefore,
the pilot clinical trial was designed to test the hypothesis
that the administration of Danlou tablets would attenuate
progressive LV dilatation after acute MI.
Methods
Patient population
Patients included in our study were aged 18 to 80 years
with typical chest pain lasting for at least 30 min and a
subsequent rise in specific cardiac biomarkers of myo-
cardial injury [creatine kinase-MB (CKMB) or troponin
T (TnT)] to more than 3 times the normal upper limit,
and admitted with acute MI who successfully underwent
revascularization (percutaneous coronary intervention,
PCI) of the infarct-related artery. Eligible patients also
met the diagnostic criteria of intermingled phlegm and
blood stasis syndrome according to the criteria for TCM
syndrome differentiation of patients with coronary heart
disease, published by the Chinese Interactive Medicine
Association.
Patients with previous MI within 30 days, malignant
arrhythmia, congenital heart disease, cardiac shock, docu-
mented or suspected history of heart failure or depressed
LV ejection fraction <15 %, a planned coronary artery
bypass grafting, a life expectancy of <1 year, hepatic
impairment, estimated glomerular filtration rate ≤30 mL/
min per 1.73 m2, autoimmune or connective tissue
disease, chronic substance abuse or psychiatric illness, and
who were unable to complete the 3-month clinical follow-
up were excluded in this study.
Study Design and Protocol
This randomized, prospective, double-blind, placebo-
controlled, parallel-group clinical trial was performed in
two institutions (Guangdong Provincial Hospital of CM
and Wuyi Hospital of CM). The study was conducted in
accordance with the Declaration of Helsinki and its text
revisions, and all participants provided written informed
consent before enrollment. The Clinical Research Ethical
Committee at Guangdong Provincial Hospital of CM
approved the research protocol (B2011-41-01). This trial
was registered in clinicaltrials.gov (NCT02675322).
Once eligible candidates had undergone PCI, they were
admitted to the coronary intensive care unit and received
standard treatment according to the institutional protocol
based on American College of Cardiology/ American
Heart Association and European Society of Cardiology
guidelines [20]. Simultaneously, patients were randomly
assigned in a 1:1 ratio to receive Danlou tablets (4.5 g oral
dose taken once daily) or matching placebo for 90 days,
according to a computer-generated site-stratified, block
randomization schedule. Danlou tablets were approved by
China Food and Drug Administration for the treatment of
ischemic heart disease in 2005 (Z20050244). Blinding will
be ensured using a matched placebo granule identical in
color, size, shape, and taste. The quality of the matched
trial supplies, such as contents, solubility, and bacteria
contaminations, should be controlled rigorously according
to the good manufacturing practice (GMP) standards, and
be tested and verified by researchers.
Circulating levels of CK-MB, TnT, and N-terminal
pro-brain natriuretic peptide (NT-proBNP) were systemat-
ically measured at admission time. Baseline blood test data
were collected and performed by an independent core
laboratory blinded to treatment assignment. In addition,
two-dimensional Doppler echocardiography was performed
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within 48 ± 24 h after PCI. Moreover, clinical and echocar-
diographic follow-up assessments were scheduled in all
study patients at 90 days after MI. Clinical events were
recorded by investigators from enrollment through 90 days,
whereas vital status and adverse events were collected
6 months after assignment.
The primary endpoint of the study was the change in
the LVEDVi (ΔLVEDVi), as measured by two-dimensional
(2D) echocardiography from baseline to 90 days. Second-
ary study endpoints were changes in LVESVi (ΔLVESVi)
and LVEF (ΔLVEF) during the same interval. In addition,
the occurrence and composite of major adverse cardiovas-
cular events (MACE), in terms of cardiac death, recurrent
MI, and target vessel revascularization, cardiogenic shock,
severe heart failure (hospital readmission for congestive
heart failure and/or worsening NYHA class III-IV) and
major arrhythmia were assessed and recorded during
hospitalization and up to 90 days thereafter. Additional
endpoints included the assessment in safety outcomes
during the period of follow-up (mean 6 months).
Echocardiographic imaging and analyses
Echocardiograms were performed by experienced sono-
graphers using a commercially available system (Philips
Medical Systems, Andover, MA, USA) for LV dimension
and ejection fraction quantification. Standard 2D images
and Doppler data were obtained using the standard
apical 2- and 4- chamber views, according to the
recommendations of the American Society of Echocardi-
ography [21]. The echocardiograms were analyzed
centrally, according to predefined procedures in the core
laboratory at the Guangdong Provincial Heart Center by
technicians supervised by two cardiologists, all of them
blinded to the randomized assignment and examination
sequence (baseline vs. follow-up assessment). The LV
long axis was measured in the apical 2- and 4-chamber
views from the apex tip to the anterior/lateral corner of
the mitral annulus. Biplane end diastolic and systolic
volumes were calculated using the modified Simpson’s
rule. Three cycles were measured for each assessment,
and the average volumes were obtained. The LVEDVi
and LVESVi were then calculated as LVEDV and LVESV
divided by body surface area. The LV ejection fraction
was calculated using the multiple diameter method,
which uses the average of the LV diameters measured at
end-diastole and end-systole from the parasternal long
axis and apical views together along with an estimate of
fractional long axis shortening. Pulsed-wave Doppler of
transmitral flow was used to assess global diastolic
function, by placing the sample volume between the tips
of the mitral leaflets, peak early velocity (E), peak atrial
velocity (A), and E-wave deceleration time (EDT) were
measured [22]. Internal review of the first 60 paired
echocardiograms (baseline and day 90) was performed
and verified (<10 % interobserver variability in LV
dimension and ejection fraction measurements).
Statistical analysis
To calculate the target sample size for the present study,
we hypothesized that Danlou tablets would decrease the
LVEDVi by 8 %. An estimated sample size of 80 patients
(40 per group) would be needed to detect the difference
with a statistical power 90 % and a probability type I
error of 5 %, considering an attrition rate of 10 %. Base-
line characteristics were presented with mean ± standard
deviation (SD) or median and interquartile range (IQR)
for continuous variables, and with numbers and percentages
(%) for categorical variables. The analysis would be
performed based on the intent-to-treat (ITT) principle. Con-
tinuous variables were compared within each group using
Student’s t-test or the Wilcoxon rank-sum test (if non-
normally distributed), whereas the categorical variables were
compared using chi-square statistics or Fisher’s exact test
when appropriate. To compare the means of basal echocar-
diography data between groups, two-sided Student’s t-tests
were used. 90-day changes from baseline in LVEDVi,
LVESVi and LVEF were compared between groups using
analysis of covariance with major determinants, including
age, concomitant systemic hypertension, diabetes mellitus,
peak CK-MB, peak NT-proBNP levels, treatment with beta
adrenergic blockers and ACE inhibitors (or ARB), and
corresponding baseline echocardiogaphic values that could
explain the LV remodeling as covariates. The treatment
effect of Danlou tablets (mean difference in change of
LVEDVi, LVESVi and LVEF) was estimated using adjusted
least square means from this model, with associated
two-sided 95 % confidence intervals (CI) and P-values
(significance level set at 5 %). Statistical analysis was




In total, 106 patients with MI were screened for the
study, and initially 88 were included (44 Danlou tablets
and 44 placebo; Fig. 1). Five patients were excluded,
leaving 83 patients (94.3 % of the initial set, 42 Danlou
tablets and 41 placebo) for analysis. The reasons for
exclusion included the poor quality of echocardiographic
imaging (insufficient resolution of LV endocardial border),
no follow-up recording and consent withdrawal. The
clinical characteristics of the study population at baseline
are shown in Table 1.
Study groups were well matched overall without clinically
relevant differences in demographic variables, cardiovascu-
lar risk factors, concomitant diseases, clinical presentation,
or discharge medical therapy. The mean age of the popula-
tion was 67.97 ± 9.41 years. The majority of patients were
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men (62.50 %). Mean resting heart rate at baseline was
76.13 ± 13.15 bpm. Comparing the main procedural
features in both groups, there were no statistically signifi-
cant differences in multivessel lesion type, procedural char-
acteristics of intervention, number of stents per patient,
and diameter and length of implanted stents (P > 0.05,
respectively). The patients were evenly distributed between
New York Heart Association (NYHA) function classes II
to III, along with similar baseline NT-proBNP levels
[1419.27 pg/mL (IQR, 293.41 to 2678.54) vs. 1147.21 pg/
mL (IQR, 240.50 to 2675.61), P = 0.55]. Patients in both
treatment groups had high rates (exceeding 90 %) of
beta-blocker and rennin angiotensin aldosterone system
(RAAS) antagonist use.
Echocardiographic findings
Table 2 and Fig. 2 present echocardiographic LV remodel-
ing results from baseline to 90 days. Baseline LVEDVi was
similar in the Danlou tablets and placebo groups (49.22 ±
8.70 vs. 51.33 ± 9.61 mL/m2, respectively, P > 0.05). Treat-
ment with Danlou tablets for 90 days was associated with
a significant reduction in LVDSVi as compared with the
placebo (−4.49 ± 7.29 vs. −0.34 ± 9.01 mL/m2, mean differ-
ence −5.86, 95 % CI −7.55 to −4.16, P < 0.001).
The values of the LVESVi were similar at baseline in the
Danlou tablets and placebo groups (31.79 ± 5.29 vs. 31.05
± 6.02, P > 0.05). From baseline to 90-day follow-up,
LVESVi remained substantially unchanged in the control
group, whereas it was significantly decreased in the Danlou
tablets group (−0.54 ± 5.72 vs. −4.09 ± 5.85 mL/m2, mean
difference −3.20, 95 % CI −4.43 to −1.98, P < 0.001).
Consequently, the increase from baseline to the 90-day
follow-up of LVEF was higher in the Danlou tablets group
than in the control group (4.83 ± 9.23 and 0.23 ± 8.15 %,
mean difference 3.15, 95 % CI 1.66 to 4.63, P <0.001).
Clinical follow-up
The adherence of patients to therapy was fully respected.
Overall, no patients in either Danlou tablets or placebo
group died during their hospital stay and during the
follow-up periods. However, 9 patient (21.95 %) from the
placebo group and 5 patients (11.90 %) treated with
Danlou tablets had a non-fatal recurrent MI. Also, 1
patient (out of 42) from the Danlou tablets group
(2.38 %) and 5 patients (out of 41) in the placebo group
(12.20 %) developed a severe heart failure. Moreover, 2
patients from the placebo (4.88 %) demonstrated symp-
toms of the cardiogenic shock and 1 patient (2.44 %)
had a major arrhythmia. Importantly, these complica-
tions did not developed in patients receiving Danlou tab-
lets. In total, the incidence of composite of reinfarction,
severe heart failure, cardiogenic shock and arrhythmia
was higher in the placebo group than in the Danlou
tablets group (11.90 vs. 34.15 %, P = 0.02).
Finally, we like to state that all patients were closely
monitored by a set of drug safety analyses. Results of their
statistical evaluation indicated that apart of occasional
dyspepsia symptoms occurring in Danlou tablet-treated pa-
tients, we did not detect any serious adverse events related
to our trial during the follow-up period (data not shown).
Discussion
Adverse LV remodeling commonly occurs after MI, des-
pite the successful coronary reperfusion and application of
several classic pharmacological interventions. It often
causes a progressive LV dilation that compromises the
overall myocardial contractility and eventually culminates
in heart failure [23]. Therefore, recent attempts, including
the present study, have been aimed at limiting the patho-
logical progress of LV remodeling by administration of
certain natural agents derived from complementary and
alternative medicine [24].
Fig. 1 Trial profile. The number of patients who were enrolled in the study and included in the analyses. MI, myocardial infarction; FAS, full
analysis set
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Results of the double-blind, randomized and placebo-
controlled clinical trial demonstrated that treatment with
Danlou tablets (combined with standard pharmacological
agents) significantly reduced rates of adverse LV remodel-
ing (ΔLVEDVi and ΔLVESVi) and improved the overall
clinical outcomes in patients afflicted with acute MI.
Danlou Tablets consist of 11 types of herbs, all of which
are included in the Chinese pharmacopoeia. UPLC-MS/
MS was also used to analyse 15 quality-control markers of
Danlou Tablet, and good consistency of the active markers
was found among 8 different batches, including tanshi-
none IIA, danshen su, puerarin, daidzin, salvianolic acid B,
Table 1 Baseline characteristics data
Danlou tablets (n = 44) Placebo (n = 44) P
Age, yr 67.54 ± 8.39 68.38 ± 10.41 0.18
Male sex, no. (%) 28 (63.64) 27 (61.36) 0.83
BMI, kg/m2 22.29 ± 4.78 23.99 ± 3.12 0.35
Heart rate (beats/min) 75.41 ± 13.69 78.84 ± 13.36 0.57
Systolic blood pressure (mmHg) 126.44 ± 26.43 123.42 ± 27.18 0.85
Concomitant diseases, no. (%)
Previous coronary heart disease 12 (27.27) 15 (34.09) 0.49
Systemic hypertension 21 (47.73) 23 (52.27) 0.67
Diabetes mellitus 9 (20.45) 10 (22.73) 0.80
Dyslipidemia 12 (27.27) 18 (40.91) 0.18
Current smoker, no.(%) 14 (31.82) 12 (27.27) 0.64
NYHA Class
Class I 4 (9.09) 5 (11.36) 0.99
Class II 20 (45.46) 19 (43.18)
Class III 18 (40.91) 17 (38.64)
Class IV 2 (4.54) 3 (6.82)
Procedural Features
LAD (%) 35 (79.55) 32 (72.73) 0.45
Multivessel disease (%) 14 (31.82) 19 (43.18) 0.39
Procedural success (%) 44 (100) 44 (100) 1.00
Stenting of IRA (%) 44 (100) 44 (100) 1.00
Multiple stenting (%) 10 (22.73) 8 (18.18) 0.60
Total length of stenting (mm) 20.52 ± 7.01 22.37 ± 6.46 0.22
TIMI flow grade 3 after PCI (%) 44 (100) 44 (100) 1.00
Procedural time (min) 62.68 ± 19.72 65.32 ± 19.55 0.51
Cardiac biomarker
Peak CK-MB (IU/L) 68.01 [46.83–99.90] 64.34 [19.65–97.98] 0.21
NT-proBNP (pg/mL) 1419.27 [293.41–2678.54] 1147.21 [240.50–2675.61] 0.55
Therapy, no. (%)
Aspirin 42 (95.45) 43 (97.73) 0.56
Clopidogrel 44 (100) 44 (100) 1.00
Statin 44 (100) 44 (100) 1.00
Beta adrenergic blockers 40 (90.91) 41 (93.18) 0.69
ACE inhibitors (or ARB) 41 (93.18) 42 (95.45) 0.65
Aldosterone antagonist 5 (11.36) 4 (9.09) 0.73
Digitalis 8 (18.18) 6 (13.64) 0.56
Data are presented as mean ± SD or median [interquartile range] or numbers (%) when appropriate
ACE denotes angiotensin converting enzyme, ARB angiotensin II receptor blocker, BMI body mass index, CK-MB creatine kinase-MB, IRA infarct-related artery, LAD
left anterior descending artery, LVEF left ventricular ejection fraction, N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association, PCI percutaneous
coronary intervention, TIMI thromobolysis in myocardial infarction
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and salvianolic acid A (Additional file 1). The most
important determinants characterizing the magnitude and
kind of LV remodeling are the actual size of the infarct,
the existence of microcirculation in the ischemic zone, as
well as the quality and quantity of the newly deposited
extracellular matrix (ECM). The Danlou tablet-related
improvements of LV remodeling are probably due to its
established multiple effects which play vital roles in
reversing the pathological remodeling process. Previously
published studies of experimental infarcts in animal
models suggested that Danlou tablets may protect vascu-
lar endothelium and improve formation of new capillaries
on the edges of the ischemic myocardial zones, thereby
contributed to the ultimate reduction of the infarct size,
promotion of myocardial healing and subsequent allevi-
ation of the progressive ventricular fibrosis [25–27]. Our
previous studies performed on cultured human cardiac
fibroblasts further confirmed that tanshinone IIA, an
effective component of Danlou tablets, significantly inhib-
ited the deposition of collagen fibers which exacerbate
mechanical stiffness and reduced contractility, but simul-
taneously enhanced production of new elastic fibers
contributing to more resilient matrix [28, 29]. Since the
optimal proportions of these ECM components eventually
determine the beneficial healing of the infarcted myocar-
dium, we speculate that addition of the Danlou tablets to
the classic Western pharmacological therapy of our MI
patients, likely shifted the initial adverse remodeling
processes toward the ultimate regeneration and formation
of the more elastic post-infarct scars, complying with the
action of the initially injured hearts and preserving global
contractility and compliance. Moreover, results of only
few clinical reports also suggested that administration of
Danlou tablets in patients with ischemic heart disease
induced improvement of clinical angina symptoms and
decreased frequency of major atherothrombotic complica-
tions (plaque rupture and thrombosis) that eventually lead
to MI [30]. However, up to date the observed beneficial
effects of Danlou tablets have not been mechanistically
confirmed by the adequate randomized, prospective,
double-blind, placebo-controlled clinical trial.
The 90-day long duration of this pilot study was
encouraged by previous clinical studies indicating that
this time is always sufficient for the objective
echocardiographic assessment of the changes in
LVEDVi [31]. Therefore, we used echocardiography for
a standard evaluation of LV remodeling, because this
readily available technique permitted for the quick and
efficient screening of potential patients, and allowed us
for a fair estimation of the benefits of ACE inhibitors
and beta-blockers on LV volumes and ejection fractions
[32, 33]. During the serial LV remodeling measure-
ments, we detected some individual variability, but its
range was rather similar in both tested groups and pro-
vided us with an adequate statistical power to revaluate
the variation.
Several limitations in this study should be acknowl-
edged. Despite the fact that the indirect measures of
myocardial enzyme (peak CK-MB) levels, ventricular
wall stress (peak pro-BNP) and myocardial reperfusion
effectiveness (TIMI flow grade 3 after PCI) did not
significantly differ between both experimental groups
(Table 1), we are aware that without quantitative assess-
ment of infarct size and myocardial viability at baseline,
a potential selection bias favoring the Danlou tablet ther-
apy arm could not be entirely excluded. While the prog-
nostic value of LVEF assessed early after MI has been
previously demonstrated by other studies, we are con-
scious that results of echocardiography, performed early
(within 48 h) after MI, might underestimate the LVEF
due to stunning of the myocardium [34]. Despite the
above mentioned limitations of our pilot trial, we hope
that further studies testing the larger populations will ul-
timately justify the beneficial impact of Danlou tablets
on the post-MI adverse LV remodeling.
Conclusion
Results of our preliminary clinical trial demonstrated
that LVEDVi and LVESVi were significantly smaller in
MI patients who received Danlou tablets, as compared
to their placebo-treated counterparts. They strongly in-
dicated that addition of this TCM remedy to the stand-
ard reperfusion and conventional pharmacologic medical
intervention, should be considered as a promising thera-
peutic approach, aimed at alleviation of the adverse LV
remodeling and preserving cardiac function in patients
afflicted with acute MI. Therefore, encouraged by the
Table 2 Echocardiogaphic LV remodeling end points
Danlou tablets (n = 42) Placebo (n = 41) Danlou tablets vs. Placebo P
Baseline 90 days Change Baseline 90 days Change Difference in change (95 % CI)
LVEDVi, mL/m2 49.22 ± 8.70 44.73 ± 4.29 −4.49 ± 7.29 51.33 ± 9.61 50.99 ± 3.55 −0.34 ± 9.01 −5.86 (−7.55 to −4.16) <0.001
LEVSVi, mL/m2 31.79 ± 5.29 27.69 ± 2.46 −4.09 ± 5.85 31.05 ± 6.02 30.51 ± 3.12 −0.54 ± 5.72 −3.20 (−4.43 to −1.98) <0.001
LVEF,% 44.76 ± 7.95 49.59 ± 3.29 4.83 ± 9.23 46.79 ± 8.03 46.53 ± 2.97 0.23 ± 8.15 3.15 (1.66 to 4.63) <0.001
Values are expressed as means ± SD when appropriate
CI confidence interval, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, LVEF left ventricular ejection fraction
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up-today results, we will continue and extend the
ongoing clinical trial after randomly assigning 280 more
patients with the angiography-confirmed acute MI that
could be followed up to 6 months.
Additional file
Additional file 1: UPLC fingerprints of Danlou Tablets. (TIF 732 kb)
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